The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Share News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.857%)
Open: 17.75
High: 17.75
Low: 17.75
Prev. Close: 17.75
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Safestyle suffers amid "difficult" trading conditions

Wed, 27th Sep 2023 13:10

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Safestyle UK PLC - Bradford-based retailer and manufacturer of PVCu replacement windows and doors - Revenue in half-year ended July 2 declines 5.3% on-year to GBP74.1 million from GBP78.3 million. Pretax loss widens to GBP6.7 million from GBP2.8 million. Decides against interim dividend, after 0.4 pence per share payout a year prior. "The trading context of the UK economy and consumer confidence remains extremely difficult. Encouragingly, inflation is beginning to show some signs of moderating, but that follows a period of sustained high inflation. The impact of significantly higher interest rates than expected is clearly impacting consumers' disposable income," Safestyle says.

----------

Zegona Communications PLC - London-based company focused on communications and entertainment opportunities - Pretax loss in six months to June narrows slightly to EUR1.8 million from EUR1.9 million. Generates no revenue, unchanged year-on-year. Zegona adds: "Over the last 6 months we have continued to focus on identifying and pursuing the right opportunity within the European telecommunications market where we can again successfully apply our proven "buy-fix-sell" strategy to generate attractive returns for our shareholders. We remain patient and disciplined in our approach and are encouraged by the stabilisation in both the economic outlook and telecommunications market trends, which contribute to the confidence we have in our ability to find the right next investment for Zegona." On Friday, it confirmed it was in talks with Vodafone Group PLC to acquire its Spanish operations. Zegona said the deal remains subject to agreement on final terms with Vodafone, completion of its due diligence and formalisation of funding arrangements. As a result, it stressed that there is "no certainty" that the potential acquisition will go ahead, nor as to any of the final terms if a deal were to be struck.

----------

ProBiotix Health PLC - Wakefield, England-based life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions - Pretax loss in six months to June 30 widens to GBP512,000 from GBP251,000 a year prior. It reports "other administrative costs" more than double to GBP668,000 from GBP274,000. Revenue rises 83% to GBP552,000 from GBP302,000. Chief Executive Officer Steen Andersen says: "Since I took over as CEO in January 2023, my focus has been on building and developing a defined strategy whereby we are looking to become a solutions provider of finished probiotic products in consumer formats. My objective is to build ProBiotix into a GBP10 million plus turnover company, marketing our products both under our own brands and partner private labels. We are excited about the future of the company and remain committed to providing long term value to our shareholders."

----------

OptiBiotix Health PLC - York, England-based life sciences company, which develops edible compounds to tackle chronic conditions like obesity and diabetes - Swings to pretax loss of GBP1.9 million in first six months of 2023, from profit of GBP13.9 million a year prior. In the prior year, it booked a GBP21.6 million profit on the disposal of a subsidiary. It registers no such gains this time around. Revenue rises to GBP351,000 from GBP119,000. CEO Stephen O'Hara says: "The aim for the second half of the year is to maintain our focus on managing costs, growing sales and closing out ongoing discussions with a number of larger partners across first and second-generation products to ensure a return on investment from the expansion of our commercial and business development teams."

----------

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Revenue in year ended June 30 falls 16% to GBP61.0 million from GBP72.8 million. Allergy's pretax loss stretches to GBP49.8 million from GBP12.7 million. "This financial year has been challenging, however, the group has made good progress in recovering manufacturing capacity and developing robust quality systems that are well-placed to support future growth," CEO Manuel Llobet says.

----------

Fadel Partners Inc - media rights and royalty management software developer - Revenue in half-year ended June 30 declines 20% to USD5.4 million from USD6.7 million a year earlier. Pretax loss widens to USD1.3 million from USD1.1 million. CEO Tarek Fadel says: "The outlook for Fadel remains positive and the benefits of our investments are already coming through as the strong trading momentum enjoyed in 1H23 continues into the second half of the year. Investments made in the business to date, alongside the wider shift towards digitisation, are driving increased demand for our offering and give great confidence in the group's outlook."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Mar 2024 17:08

OptiBiotix Health raises GBP1.4 million to invest in "driving sales"

(Alliance News) - OptiBiotix Health PLC on Monday said it has raised GBP1.4 million through a placing and subscription of shares.

Read more
13 Mar 2024 20:49

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Mar 2024 14:28

OptiBiotix signs partnership with India's Dr Morepen

(Sharecast News) - Life science company OptiBiotix Health announced the signing of a partnership agreement with Dr Morepen on Wednesday, for the distribution of SlimBiome products in India under the Dr Morepen brand.

Read more
27 Feb 2024 12:57

OptiBiotix products return to sales growth as pipeline strong

(Alliance News) - OptiBiotix Health PLC shares rose on Tuesday as the firm celebrated a "gradual return to strong sales growth".

Read more
30 Jan 2024 13:35

IN BRIEF: OptiBiotix in discussions for launch of SweetBiotix

OptiBiotix Health PLC - York, England-based life sciences company - Hails "significant progress" in SweetBiotix commercial scale production. Says it is currently in discussions with commercial partners to launch SweetBiotix products. SweetBiotix is a low calorie alternative to sugar. Chief Executive Officer Stephen O'Hara says: "Consumer concerns over sugar and the safety of several sugar substitutes have materialised into companies reformulating existing and/or launching new products containing natural, safe, and healthy alternatives. The company believes its sweet, high fibre, low calorie, prebiotic fibre SweetBiotix products are ideally positioned to launch at a time when many companies are actively looking for a natural alternative to meet this need."

Read more
15 Jan 2024 11:34

OptiBiotix to launch LeanBiome with Muscletech

(Sharecast News) - OptiBiotix Health announced the upcoming launch of LeanBiome in partnership with prominent sports nutrition brand Muscletech on Monday.

Read more
15 Jan 2024 10:40

OptiBiotix's LeanBiome to be launched under MuscleTech

(Alliance News) - OptiBiotix Health PLC on Monday announced the launch of LeanBiome in sports nutrition brand, MuscleTech.

Read more
4 Dec 2023 12:23

IN BRIEF: OptiBiotix names Croda's Graham Myers as finance director

OptiBiotix Health PLC - York, England-based life sciences company - Appoints Graham Myers as finance director, effective as of December 1, 2023. Says that Myers' appointment to this part-time role will see him work closely with the OptiBiotix team to support its focus on "driving each business unit and the group to profitability". Myers is currently chair of Croda Pension Trustees Ltd, the sole trustee of Croda International PLC's GBP800 million UK pension scheme.

Read more
28 Nov 2023 14:57

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:15

EARNINGS AND TRADING: Victorian Plumbing profit up; Duke revenue dips

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
1 Nov 2023 12:58

OptiBiotix makes strong progress in e-commerce shift

(Sharecast News) - OptiBiotix Health reported significant progress in its commercial endeavours in an update on Wednesday, as it looked to attain profitability at the business unit level, ultimately leading to overall profitability.

Read more
1 Nov 2023 11:55

OptiBiotix says market still "volatile" but partner sales improving

(Alliance News) - OptiBiotix Health PLC on Wednesday said sales from existing partners have improved in recent months, and that its move to focus on US and Asian markets is progressing well.

Read more
23 Oct 2023 10:17

OptiBiotix adds Tata Chemicals ingredient to obesity product in India

(Alliance News) - OptiBiotix Health PLC on Monday said it agreed a licence deal with Tata Chemicals Ltd to incorporate Tata's short-chain fructo-oligosaccharide Fossence into OptiBiotix's SlimBiome and LeanBiome products for the Indian market.

Read more
23 Oct 2023 08:16

OptiBiotix inks ingredient deal with Tata Chemicals

(Sharecast News) - Life sciences developer OptiBiotix Health announced a significant agreement with Tata Chemicals on Monday, that would see its proprietary 'Fossence' product incorporated into their 'SlimBiome' and 'LeanBiome' product lines, specifically tailored for the Indian market.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.